Arbutus Biopharma (ABUS) Research & Development (2016 - 2025)
Historic Research & Development for Arbutus Biopharma (ABUS) over the last 17 years, with Q3 2025 value amounting to $5.8 million.
- Arbutus Biopharma's Research & Development fell 5951.8% to $5.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $29.0 million, marking a year-over-year decrease of 5374.34%. This contributed to the annual value of $54.0 million for FY2024, which is 2667.98% down from last year.
- Arbutus Biopharma's Research & Development amounted to $5.8 million in Q3 2025, which was down 5951.8% from $5.5 million recorded in Q2 2025.
- In the past 5 years, Arbutus Biopharma's Research & Development ranged from a high of $22.9 million in Q4 2022 and a low of $5.5 million during Q2 2025
- For the 5-year period, Arbutus Biopharma's Research & Development averaged around $15.7 million, with its median value being $16.7 million (2021).
- Its Research & Development has fluctuated over the past 5 years, first surged by 5096.99% in 2021, then tumbled by 6464.54% in 2025.
- Over the past 5 years, Arbutus Biopharma's Research & Development (Quarter) stood at $19.2 million in 2021, then increased by 19.45% to $22.9 million in 2022, then decreased by 23.47% to $17.6 million in 2023, then tumbled by 49.84% to $8.8 million in 2024, then crashed by 34.42% to $5.8 million in 2025.
- Its last three reported values are $5.8 million in Q3 2025, $5.5 million for Q2 2025, and $9.0 million during Q1 2025.